The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | The role of integrins in resistance to BTK inhibitors in CLL
Tanja Nicole Hartmann, MD, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany, describes key aspects of the chronic lymphocytic leukemia (CLL) tumor microenvironment, commenting on integrins, and how these may play a role in drug resistance against BTK inhibitors. Dr Hartmann also explains the importance of further understanding the signaling cascades involved and the interaction between B-cells and integrins in the CLL tumor microenvironment to identify what therapies can be combined with BTK inhibitors to minimize drug resistance and toxicity. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
